Improved Locoregional Recurrence‐Free Survival With Carbon Ion Versus Photon Radiotherapy in Locally Advanced Non‐Small Cell Lung Cancer
Cancer Medicine · 2026
DOI: 10.1002/cam4.72229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yonglong Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Heavy Ion Radiotherapy, Lung Neoplasms, Photons. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Carbon ion radiotherapy (CIRT) delivers high linear energy transfer radiation with superior dose conformity compared with photon radiotherapy (PRT). However, whether these physical advantages translate into clinical benefit for locally advanced non‐small cell lung cancer (LA‐NSCLC) in the era of modern systemic therapy remains unclear.
Methods
We performed a retrospective, propensity score‐matched cohort study of patients with Stage III LA‐NSCLC treated with definitive CIRT or PRT as part of multimodality therapy between January 2016 and December 2023. The primary endpoint was locoregional recurrence‐free survival (LRFS). Secondary endpoints included progression‐free survival (PFS), overall survival (OS), distant metastasis‐free survival (DMFS), and acute grade ≥ 2 radiation‐related adverse events (AEs).
Results
A total of 292 patients were matched (146 per group). With a median follow‐up of 32.5 months, CIRT group demonstrated significantly longer median LRFS (57.7 vs. 25.0 months; HR, 0.59; 95% CI, 0.39–0.88; p = 0.01) and median PFS (17.7 vs. 16.7 months; HR, 0.70; 95% CI, 0.53–0.94; p = 0.02) compared with PRT group, whereas OS and DMFS were similar between groups. CIRT group also had fewer acute grade ≥ 2 radiation‐related AEs.
Conclusions
CIRT demonstrated improved locoregional control and fewer acute toxicities compared with PRT in LA‐NSCLC in this retrospective matched cohort. Prospective randomized trials are warranted to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
- Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China.
ORCID-Profile: Yonglong Liu, Xingwen Fan, Kailiang Wu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Ma, N., Li, Y., Mi, J., Fan, X., Chen, J., Mao, J., Jiang, G., & Wu, K. (2026). Improved Locoregional Recurrence‐Free Survival With Carbon Ion Versus Photon Radiotherapy in Locally Advanced Non‐Small Cell Lung Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.72229
Vancouver
Liu Y, Ma N, Li Y, Mi J, Fan X, Chen J, et al. Improved Locoregional Recurrence‐Free Survival With Carbon Ion Versus Photon Radiotherapy in Locally Advanced Non‐Small Cell Lung Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.72229
BibTeX
@article{Liu2026,
author = {Liu, Yonglong and Ma, Ningyi and Li, Yaqi and Mi, Jing and Fan, Xingwen and Chen, Jian and Mao, Jingfang and Jiang, Guoliang and Wu, Kailiang},
title = {Improved Locoregional Recurrence‐Free Survival With Carbon Ion Versus Photon Radiotherapy in Locally Advanced Non‐Small Cell Lung Cancer},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72229}
}
EUVIMED